Zobrazeno 1 - 10
of 211
pro vyhledávání: '"Arnoud J, Templeton"'
Autor:
Stefanie Fischer, Silke Gillessen, Odile Stalder, Angelika Terbuch, Richard Cathomas, Florian A. Schmid, Deborah Zihler, Beat Müller, Christian D. Fankhauser, Anita Hirschi-Blickenstorfer, Luis Alex Kluth, Bettina Seifert, Arnoud J. Templeton, Walter Mingrone, Mark-Peter Ufe, Natalie Fischer, Jörg Beyer, Regina Woelky, Aurelius Omlin, Ursula Vogl, Katharina Hoppe, Jörn Kamradt, Sacha I. Rothschild, Christian Rothermundt
Publikováno v:
European Urology Open Science, Vol 68, Iss , Pp 68-74 (2024)
Background and objective: Follow-up for patients with testicular cancer should ensure early detection of relapses. Optimal schedules and minimum requirements for cross-sectional imaging are not clearly defined, and guideline recommendations differ. O
Externí odkaz:
https://doaj.org/article/cf3f1f7b4c80443686e599e578c8dbdd
Autor:
Stefanie Fischer, Christian Rothermundt, Odile Stalder, Angelika Terbuch, Thomas Hermanns, Deborah Zihler, Beat Müller, Christian D. Fankhauser, Anita Hirschi-Blickenstorfer, Bettina Seifert, Luis Alex Kluth, Mark-Peter Ufe, Walter Mingrone, Arnoud J. Templeton, Natalie Fischer, Sacha Rothschild, Regina Woelky, Silke Gillessen, Richard Cathomas
Publikováno v:
European Urology Open Science, Vol 50, Iss , Pp 57-60 (2023)
The tumour markers alpha-fetoprotein (AFP), beta human chorionic gonadotropin (βHCG), and lactate dehydrogenase (LDH) have established roles in the management and follow-up of testicular cancer. While a tumour marker rise can serve as an indicator o
Externí odkaz:
https://doaj.org/article/6b392f93b5874dadb0ac979caa21880c
Autor:
Arnoud J. Templeton, Aurelius Omlin, Dominik Berthold, Jörg Beyer, Irene A. Burger, Daniel Eberli, Daniel Engeler, Christian Fankhauser, Stefanie Fischer, Silke Gillessen, Guillaume Nicolas, Stephanie Kroeze, Anja Lorch, Michael Müntener, Alexandros Papachristofilou, Niklaus Schaefer, Daniel Seiler, Frank Stenner, Petros Tsantoulis, Tatjana Vlajnic, Thomas Zilli, Daniel Zwahlen, Richard Cathomas
Publikováno v:
Swiss Medical Weekly, Vol 153, Iss 8 (2023)
The management of prostate cancer is undergoing rapid changes in all disease settings. Novel imaging tools for diagnosis have been introduced, and the treatment of high-risk localized, locally advanced and metastatic disease has changed considerably
Externí odkaz:
https://doaj.org/article/253dd9f4666147ea9d85f1bee5fa5a4c
Autor:
Beat Bojaxhiu, Dubravko Sinovcic, Olgun Elicin, Arnoud J. Templeton, Mohamed Shelan, Jan Wartenberg, Ian Alberts, Axel Rominger, Daniel M. Aebersold, Kathrin Zaugg
Publikováno v:
Radiation Oncology, Vol 17, Iss 1, Pp 1-13 (2022)
Abstract Background Systemic inflammation is predictive of the overall survival in cancer patients and is related to the density of immune cells in the tumor microenvironment of cancer, which in turn correlates with 18F -fluorodeoxyglucose (FDG)-posi
Externí odkaz:
https://doaj.org/article/dd9f2e28deda40afad1afb48ec39ecd4
Autor:
Ailsa J. Christiansen, João Lobo, Christian D. Fankhauser, Christian Rothermundt, Richard Cathomas, Aashil A. Batavia, Josias B. Grogg, Arnoud J. Templeton, Anita Hirschi-Blickenstorfer, Anja Lorch, Silke Gillessen, Holger Moch, Jörg Beyer, Thomas Hermanns
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionCurrent evidence shows that serum miR-371a-3p can identify disease recurrence in testicular germ cell tumour (TGCT) patients and correlates with tumour load. Despite convincing evidence showing the advantages of including miR-371a-3p test
Externí odkaz:
https://doaj.org/article/9039fb352c16400a82b9ed88cda7aed2
Autor:
Manolis Pratsinis, Christian Fankhauser, Katerina Pratsinis, Jörg Beyer, Emanuel Bührer, Richard Cathomas, Natalie Fischer, Thomas Hermanns, Anita Hirschi-Blickenstorfer, Jörn Kamradt, Luis Alex Kluth, Deborah Zihler, Walter Mingrone, Beat Müller, Tim Nestler, Sacha I. Rothschild, Bettina Seifert, Arnoud J. Templeton, Angelika Terbuch, Mark-Peter Ufen, Regina Woelky, Silke Gillessen, Christian Rothermundt
Publikováno v:
European Urology Open Science, Vol 40, Iss , Pp 16-18 (2022)
Incidental detection of urogenital tumors has increased in recent decades owing to the greater use of ultrasonography and cross-sectional imaging. For patients with low-risk prostate cancer or small renal masses, active surveillance represents a vali
Externí odkaz:
https://doaj.org/article/ac4d6092c3374895896066d59118f6f2
Autor:
Domen Ribnikar, Hadar Goldvaser, Zachary W. Veitch, Alberto Ocana, Arnoud J. Templeton, Boštjan Šeruga, Eitan Amir
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Data suggest that for newly approved cancer drugs safety and tolerability are worse than in control arms of registration trials. Less is known about the balance between efficacy and toxicity of drugs studied in unselected phase 3 randomized
Externí odkaz:
https://doaj.org/article/1b46992acee94202aa4a2afa74817e81
Autor:
Domen Ribnikar, Igor Stukalin, Philippe L. Bedard, Robert J. Hamilton, Michael Jewett, Padraig Warde, Peter Chung, Lynn Anson-Cartwright, Arnoud J. Templeton, Eitan Amir, Aaron R. Hansen, Daniel Y. C. Heng, Jeremy Lewin
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 107-114 (2020)
We investigated the prognostic utility of pre-chemotherapy neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors (GCTs) undergoing first-line chemotherapy. We utilized two institutional databases to analyze the pretreatmen
Externí odkaz:
https://doaj.org/article/74268072d0d94d00b13168f8a9e2b0f1
Autor:
Ramy R. Saleh, Nicholas Meti, Domen Ribnikar, Hadar Goldvaser, Alberto Ocana, Arnoud J. Templeton, Bostjan Seruga, Eitan Amir
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 7888-7895 (2020)
Abstract Background Anti‐cancer drugs are approved typically on the basis of efficacy and safety as evaluated in phase III randomized trials (RCTs). Health‐related quality of life (HRQoL) is a direct measure of patient benefit, but is under‐rep
Externí odkaz:
https://doaj.org/article/57f767b213a84471a8a5fbfc68906a20
Autor:
Roman Adam, Ariadna Tibau, Consolación Molto Valiente, Boštjan Šeruga, Alberto Ocaña, Eitan Amir, Arnoud J. Templeton
Publikováno v:
PLoS ONE, Vol 17, Iss 6 (2022)
Background It is unknown to what extent cancer drugs approved in Switzerland by the Swissmedic fulfil criteria of clinical benefit according to the European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS), the
Externí odkaz:
https://doaj.org/article/7872c6efa1554c6e9ce9f6c28a081198